You are here

dermatology

Eli Lilly Bags Dermatology Company Dermira for $1.1 Billion

Eli Lilly Bags Dermatology Company Dermira for $1.1 Billion

BioSpace

atopic dermatitis

Flag link:

Approval in sight, Perceptive, OrbiMed double down on Foamix's antibiotic foam to the tune of $64M

Approval in sight, Perceptive, OrbiMed double down on Foamix's antibiotic foam to the tune of $64M

Endpoints

Perceptive Advisors

Flag link:

Probiotic Derived SkinBiotix Shows Efficacy in Increasing Skin Hydration

Probiotic Derived SkinBiotix Shows Efficacy in Increasing Skin Hydration

CP Wire

SkinBioTherapeutics

clinical trials

Flag link:

Novartis first partner in RWE collaboration for dermatology

Novartis first partner in RWE collaboration for dermatology

BioCentury

PharmaSolutions

real world evidence

Flag link:

LEO Pharma and PellePharm Announce Collaboration to Advance Rare Skin Disease Therapies Worth up to $760 Million

LEO Pharma and PellePharm Announce Collaboration to Advance Rare Skin Disease Therapies Worth up to $760 Million

CP Wire

Gorlin Syndrome

Flag link:

Lilly CMO Robert Brown to lead Brickell Bio as it eyes phase 3 dermatology trials

Lilly CMO Robert Brown to lead Brickell Bio as it eyes phase 3 dermatology trials

Fierce Biotech

Flag link:

Novartis sells parts of Sandoz for $1bn

Novartis sells parts of Sandoz for $1bn

Pharmaforum

Flag link:

Allergan preludes major selloffs with $650M Almirall dermatology sale

Allergan preludes major selloffs with $650M Almirall dermatology sale

Fierce Pharma

Flag link:

Bayer sells prescription dermatology brands to Denmark's Leo Pharma

Bayer sells prescription dermatology brands to Denmark's Leo Pharma

Reuters

Flag link:

List of likely buyers of Novartis’ Dermatology division ($2bn) takes shape

List of likely buyers of Novartis’ Dermatology division ($2bn) takes shape

GoinPharma

Shanghai Fosun Pharmaceutical

Apollo Global Management

Flag link:

Aurobindo bids $1.6B for Novartis' U.S. dermatology generics: report

Aurobindo bids $1.6B for Novartis' U.S. dermatology generics: report

Fierce Pharma

Flag link:

Seasoned reps could help Aclaris' Eskata with a pleasantly surprising launch: analyst

Seasoned reps could help Aclaris' Eskata with a pleasantly surprising launch: analyst

Fierce Pharma

seborrheic keratoses

Flag link:

Novartis Weighs Sale of Dermatology Generics Business

Novartis Weighs Sale of Dermatology Generics Business

Bloomberg

Flag link:

Nestle plans to ax hundreds of R&D staffers, shutter big dermatology campus

Nestle plans to ax hundreds of R&D staffers, shutter big dermatology campus

Endpoints

Flag link:

5 Reasons Valeant's Situation Could Get Worse

5 Reasons Valeant's Situation Could Get Worse

Motley Fool

Valeant Pharmaceuticals

Flag link:

Novartis bags a new eczema drug, builds dermatology pipeline with Ziarco buyout

Novartis bags a new eczema drug, builds dermatology pipeline with Ziarco buyout

Endpoints

Flag link:

Mylan, Lupin, others now in the mix for $1.1B Bayer derm buy

Mylan, Lupin, others now in the mix for $1.1B Bayer derm buy

Fierce Pharma

Torrent Pharmaceuticals

Flag link:

Teva, Perrigo and Sun join list of suitors checking out Bayer's $1.1B derm unit

Teva, Perrigo and Sun join list of suitors checking out Bayer's $1.1B derm unit

Fierce Pharma

Teva Pharmaceutical

Flag link:

Bayer eyes $1B-plus dermatology sale to fund Monsanto quest

Bayer eyes $1B-plus dermatology sale to fund Monsanto quest

Fierce Pharma

Flag link:

Valeant Pharmaceuticals Intl Inc (VRX) May Have A Buyer For Derma Assets; Finally Some Good News?

Valeant Pharmaceuticals Intl Inc (VRX) May Have A Buyer For Derma Assets; Finally Some Good News?

Bidness, ETC

Valeant Pharmaceuticals

Flag link:

Pages